Covered recipient · General Payments record
ELVIRA LINDWALL
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$10,790.45
346 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,400.00 | 4 |
| Food and Beverage | $5,386.57 | 340 |
| Education | $3.88 | 2 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| MEDEXUS PHARMA, INC. | $5,772.29 | 36 |
| Amgen Inc. | $903.00 | 35 |
| Lilly USA, LLC | $493.53 | 30 |
| AbbVie, Inc. | $449.18 | 29 |
| Novartis Pharmaceuticals Corporation | $390.72 | 22 |
| PFIZER INC. | $365.61 | 35 |
| Celgene Corporation | $315.51 | 23 |
| GlaxoSmithKline, LLC. | $311.29 | 14 |
| Mallinckrodt Enterprises LLC | $299.58 | 21 |
| Horizon Therapeutics plc | $281.57 | 25 |
| Janssen Biotech, Inc. | $165.53 | 13 |
| Radius Health, Inc. | $153.79 | 21 |
| Vertiflex, Inc. | $130.58 | 4 |
| Amarin Pharma Inc. | $128.35 | 1 |
| Merck Sharp & Dohme Corporation | $113.33 | 9 |
| GENZYME CORPORATION | $83.12 | 5 |
| UCB, Inc. | $81.93 | 4 |
| E.R. Squibb & Sons, L.L.C. | $64.92 | 4 |
| ASSERTIO THERAPEUTICS, Inc. | $60.62 | 3 |
| Genentech USA, Inc. | $50.56 | 3 |
| Gilead Sciences, Inc. | $40.07 | 2 |
| Zyla Life Sciences | $31.88 | 2 |
| Flexion Therapeutics, Inc. | $28.87 | 1 |
| TerSera Therapeutics LLC | $27.40 | 1 |
| Janssen Scientific Affairs, LLC | $16.39 | 1 |
| Alexion Pharmaceuticals, Inc. | $16.33 | 1 |
| Ultragenyx Pharmaceutical Inc. | $14.50 | 1 |
Page 6 of 7; records 251–300 of 346 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ELVIRA LINDWALL
NPI 1881890713 · CMS profile ID 221956
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
THOUSAND OAKS, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 7; records 251–300 of 346 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1881890713?year=2019&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ELVIRA LINDWALL, NPI 1881890713, CMS profile ID 221956. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 346 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881890713?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). ELVIRA LINDWALL, NPI 1881890713, CMS profile ID 221956. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 7; records 251–300 of 346 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881890713?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- ELVIRA LINDWALL, NPI 1881890713, CMS profile ID 221956, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 7; records 251–300 of 346 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881890713?year=2019&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
346 matching records · $10,790.45 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–300 of 346.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | $22.82 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662328543 | CMS |
| MEDEXUS PHARMA, INC. | $7.74 | 04/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861457 | CMS |
| Gilead Sciences, Inc. | $26.20 | 04/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681554649 | CMS |
| AbbVie, Inc. | $5.13 | 04/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647746281 | CMS |
| Celgene Corporation | $7.29 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672774773 | CMS |
| MEDEXUS PHARMA, INC. | $7.70 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861455 | CMS |
| Merck Sharp & Dohme Corporation | $18.68 | 04/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695857293 | CMS |
| Lilly USA, LLC | $22.27 | 04/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657787323 | CMS |
| Amgen Inc. | $31.28 | 04/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662328575 | CMS |
| Horizon Therapeutics plc | $5.65 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691431231 | CMS |
| MEDEXUS PHARMA, INC. | $19.21 | 04/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861453 | CMS |
| Celgene Corporation | $7.84 | 04/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673004083 | CMS |
| PFIZER INC. | $15.45 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673072949 | CMS |
| Radius Health, Inc. | $5.67 | 04/09/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683968127 | CMS |
| Lilly USA, LLC | $21.76 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657790661 | CMS |
| Lilly USA, LLC | $21.75 | 04/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657811457 | CMS |
| AbbVie, Inc. | $7.86 | 04/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647746273 | CMS |
| E.R. Squibb & Sons, L.L.C. | $19.49 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651388005 | CMS |
| MEDEXUS PHARMA, INC. | $5.93 | 04/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861451 | CMS |
| Horizon Therapeutics plc | $2.88 | 04/02/2019 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 691431227 | CMS |
| Amgen Inc. | $28.65 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662328573 | CMS |
| GENZYME CORPORATION | $12.73 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693969759 | CMS |
| Mallinckrodt Enterprises LLC | $5.73 | 04/01/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 704814997 | CMS |
| Alexion Pharmaceuticals, Inc. | $16.33 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695596810 | CMS |
| Celgene Corporation | $3.53 | 03/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673001203 | CMS |
| Amgen Inc. | $30.92 | 03/27/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662328555 | CMS |
| Janssen Biotech, Inc. | $9.97 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658560903 | CMS |
| Lilly USA, LLC | $12.67 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657807901 | CMS |
| Merck Sharp & Dohme Corporation | $16.30 | 03/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695857805 | CMS |
| Genentech USA, Inc. | $18.86 | 03/25/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681294345 | CMS |
| MEDEXUS PHARMA, INC. | $3.65 | 03/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861449 | CMS |
| Lilly USA, LLC | $22.53 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657787335 | CMS |
| PFIZER INC. | $9.99 | 03/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673075829 | CMS |
| PFIZER INC. | $18.68 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673080951 | CMS |
| Radius Health, Inc. | $4.49 | 03/21/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683968119 | CMS |
| GlaxoSmithKline, LLC. | $13.42 | 03/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 670814489 | CMS |
| Janssen Biotech, Inc. | $13.95 | 03/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658560900 | CMS |
| Novartis Pharmaceuticals Corporation | $13.48 | 03/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659594729 | CMS |
| AbbVie, Inc. | $14.81 | 03/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647746279 | CMS |
| MEDEXUS PHARMA, INC. | $4.75 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861447 | CMS |
| Radius Health, Inc. | $21.30 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683968123 | CMS |
| Radius Health, Inc. | $7.14 | 03/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 683968125 | CMS |
| AbbVie, Inc. | $24.72 | 03/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 647746293 | CMS |
| Celgene Corporation | $4.71 | 03/11/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 672998687 | CMS |
| Amgen Inc. | $120.46 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662328551 | CMS |
| Genentech USA, Inc. | $20.04 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 681168643 | CMS |
| PFIZER INC. | $11.71 | 03/07/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673069015 | CMS |
| PFIZER INC. | $17.34 | 03/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673087851 | CMS |
| Lilly USA, LLC | $24.13 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 657794023 | CMS |
| MEDEXUS PHARMA, INC. | $6.04 | 03/04/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673861445 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $214,132.85 | 20 |
| PY2024 | Principal investigator | $671,569.47 | 18 |
| PY2023 | Principal investigator | $307,109.32 | 30 |
| PY2022 | Principal investigator | $296,666.36 | 30 |
| PY2021 | Principal investigator | $96,860.52 | 19 |
| PY2020 | Principal investigator | $15,744.15 | 4 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
20 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $250.92 | 12/31/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | A Phase 3b/4 Randomized, Double-Blind, Double Dummy, Active Comparator-Controlled Study, Comparing the Efficacy and Safety of Upadacitinib Versus Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis on a Stable Background of MTX and who had an Inadequate Response or Intolerance to a Single TNF Inhibitor (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202535099 |
| Principal investigator 1 | ABBVIE INC. | $3,047.80 | 12/04/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202527124 |
| Principal investigator 1 | ABBVIE INC. | $7,026.40 | 11/04/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202520651 |
| Principal investigator 1 | ABBVIE INC. | $51.00 | 10/09/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202515379 |
| Principal investigator 1 | Eli Lilly and Company | $20,330.00 | 09/29/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL (ATTAIN-OA PAIN) ; J2A-MC-GZT1 ; J2A-MC-GZT2 | No dispute reported | 06/30/2026 | 1187878957 |
| Principal investigator 1 | Eli Lilly and Company | $111.45 | 08/21/2025 | Non-covered Recipient Entity CARE ACCESS RESEARCH LLC | A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL | No dispute reported | 06/30/2026 | 1187877197 |
| Principal investigator 1 | ABBVIE INC. | $1,000.00 | 08/05/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202501736 |
| Principal investigator 1 | ABBVIE INC. | $3,900.00 | 07/28/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202500134 |
| Principal investigator 1 | ABBVIE INC. | $2,794.30 | 07/02/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202494423 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,842.00 | 07/02/2025 | Non-covered Recipient Entity Millennium Clinical Trials Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226108954 |
| Principal investigator 1 | ABBVIE INC. | $969.15 | 05/06/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202481525 |
| Principal investigator 1 | ABBVIE INC. | $3,800.00 | 04/08/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202474914 |
| Principal investigator 1 | ABBVIE INC. | $7,026.40 | 04/03/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202470834 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,712.00 | 03/17/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | A Multi Center Randomized Double blind Placebo controlled Parallel group Study of Nipocalimab in Adult Participants with Active Systemic Lupus Erythematosus | No dispute reported | 06/30/2026 | 1175415780 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $23,184.25 | 03/06/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | No dispute reported | 06/30/2026 | 1190311157 |
| Principal investigator 1 | ABBVIE INC. | $3,600.00 | 02/18/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202452232 |
| Principal investigator 1 | ABBVIE INC. | $14,218.77 | 02/05/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202444459 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $28,095.64 | 01/15/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS | A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol | No dispute reported | 06/30/2026 | 1190311153 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $76,258.87 | 01/09/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS | A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL | No dispute reported | 06/30/2026 | 1190311159 |
| Principal investigator 1 | ABBVIE INC. | $2,913.90 | 01/02/2025 | Non-covered Recipient Entity MILLENNIUM CLINICAL TRIALS LLC | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202434103 |